GSK's RSV vaccine accepted for regulatory review by EMA
Drugmaker said on Friday that its RSV vaccine, Arexvy, has been accepted for regulatory review by the European Medicines Agency to expand use in adults 18 years and older.
The FTSE 100-listed group noted that Arexvy was the first RSV vaccine approved in the European Economic Area for the prevention of lower respiratory tract disease caused by RSV in adults aged 60 and older, and for those aged 50-59 years who are at increased risk for RSV disease.
GSK said a European regulatory decision was expected to be reached during H126 and stated it was continuing to seek expanded indications for its RSV vaccine in other countries, including the US and Japan.
Reporting by Iain Gilbert at Sharecast.com
Disclaimer & Declaration of Interest
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.